Impel NeuroPharma to Present at the Raymond James Human Health Innovation Conference
06/16/2021 - 08:00 AM
SEATTLE, June 16, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced that the Company will present a corporate overview at the Raymond James Human Health Innovations Conference on Wednesday, June 23, 2021 at 3:20 p.m. ET.
A live webcast, if recorded, of the presentation can be accessed under “News & Events” in the Investors section of the Company’s website at https://investors.impelnp.com/investor-relations . The archived webcast will be available on the Company’s website shortly after the event.
About Impel NeuroPharma
Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD® ) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.
Contact
Investor Relations: Christina Tartaglia Stern Investor Relations Phone: (1) 212-362-1200 Email: christina.tartaglia@sternir.com
Media Relations: Melyssa Weible Elixir Health Public Relations Phone: (1) 201-723-5805 Email: mweible@elixirhealthpr.com
Impel Pharmaceuticals Inc
IMPL Rankings
N/A Ranked by Stock Gains
IMPL Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Country
US
City
Seattle
About IMPL
impel neuropharma, inc., is a privately-held, seattle-based company devoted to creating life-changing, innovative therapies for central nervous system (cns) diseases. impel's products are based on a novel nasal drug delivery platform, the pod™ device, that administers drug to the upper nasal cavity in a consistent and predictable manner. impel neuropharma is currently investigating inp104 (pod™ dhe) for acute migraine headache, inp103 (pod™ levodopa) for parkinson's disease, inp105 (pod™ olanzapine) for agitation in schizophrenia and bipolar disorders as well as inp102 (pod™ insulin) for alzheimer's disease in an nih funded trial. impel neuropharma's proprietary pod™ device enables small and large molecule drugs to be administered using a cost-effective, disposable, non-invasive intranasal drug delivery device. to learn more about impel neuropharma, please visit our website at http://impelnp.com.